ATE386527T1 - Einschlusskomplex von tuberkulostatischem rifampicin mit beta-cyclodextrin oder 2- hydroxypropyl beta-cyclodextrin und ein prozess zur herstellung desselben - Google Patents
Einschlusskomplex von tuberkulostatischem rifampicin mit beta-cyclodextrin oder 2- hydroxypropyl beta-cyclodextrin und ein prozess zur herstellung desselbenInfo
- Publication number
- ATE386527T1 ATE386527T1 AT02783368T AT02783368T ATE386527T1 AT E386527 T1 ATE386527 T1 AT E386527T1 AT 02783368 T AT02783368 T AT 02783368T AT 02783368 T AT02783368 T AT 02783368T AT E386527 T1 ATE386527 T1 AT E386527T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrin
- beta
- rifampicin
- tuberculostatic
- producing
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title abstract 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title abstract 3
- 229960001225 rifampicin Drugs 0.000 title abstract 3
- 239000001116 FEMA 4028 Substances 0.000 title abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 title abstract 2
- 229960004853 betadex Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 title abstract 2
- 230000001549 tubercolostatic effect Effects 0.000 title 1
- 239000000814 tuberculostatic agent Substances 0.000 title 1
- 229940124976 antitubercular drug Drugs 0.000 abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 2
- -1 2-hydroxy propyl cyclodextrin Chemical compound 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/281,533 US7001893B2 (en) | 2002-10-28 | 2002-10-28 | Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof |
| PCT/IB2002/004705 WO2004041284A1 (en) | 2002-10-28 | 2002-11-06 | Inclusion complex of anti-tubercular rifampicin with beta-cyclodextrin or 2-hydroxypropyl beta-cyclodextrin and a process for producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE386527T1 true ATE386527T1 (de) | 2008-03-15 |
Family
ID=32774024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02783368T ATE386527T1 (de) | 2002-10-28 | 2002-11-06 | Einschlusskomplex von tuberkulostatischem rifampicin mit beta-cyclodextrin oder 2- hydroxypropyl beta-cyclodextrin und ein prozess zur herstellung desselben |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7001893B2 (de) |
| EP (1) | EP1581226B1 (de) |
| JP (1) | JP2006509742A (de) |
| CN (1) | CN1713913A (de) |
| AT (1) | ATE386527T1 (de) |
| AU (1) | AU2002347434A1 (de) |
| WO (1) | WO2004041284A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA44385U (en) * | 2004-02-04 | 2009-10-12 | Винай Рамакант Сапте | Oral cyclodextrin composition |
| US20050171116A1 (en) * | 2004-02-04 | 2005-08-04 | Sapte Vinay R. | Enhancing the efficacy of tubercular drugs |
| EP2540696B1 (de) * | 2005-02-24 | 2020-01-01 | Diffusion Pharmaceuticals LLC | Trans-Karotinoide, deren Formulierung und Verwendung |
| US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| KR101906177B1 (ko) | 2008-12-10 | 2018-10-10 | 시플라 리미티드 | 리팍시민 복합체 |
| EP2445339B1 (de) | 2009-06-22 | 2019-08-07 | Diffusion Pharmaceuticals LLC | Verteilungsverbessernde verbindung und ihre verwendung mit einem thrombolytikum |
| WO2011126352A2 (ru) * | 2010-04-07 | 2011-10-13 | Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" | Противотуберкулезный препарат на основе комплекса включения циклодекстрина с рифампицином и способ его получения |
| AU2011262361A1 (en) | 2010-06-02 | 2013-01-10 | Diffusion Pharmaceuticals Llc | Oral formulations of bipolar trans carotenoids |
| EP4098282A1 (de) | 2016-02-04 | 2022-12-07 | Czap Research And Development, LLC | Trägerstoffe mit kontrollierter freisetzung und stratifiziertem cyclodextrineinschlusskomplex |
| CA3018550A1 (en) | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
| RU2623877C1 (ru) * | 2016-08-04 | 2017-06-29 | Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук | Способ получения полимерных комплексов рифампицина с пониженной токсичностью и высокой противотуберкулёзной активностью |
| WO2021191803A1 (en) | 2020-03-23 | 2021-09-30 | Czap Research And Development, Llc | Oral terpene cyclodextrin inclusion complex vehicles |
| CN111701034B (zh) * | 2020-07-22 | 2023-04-11 | 武汉工程大学 | 一种高水溶性利福平包合物及其制备方法 |
| CN120643524B (zh) * | 2025-06-20 | 2026-02-27 | 轩豪制药(南昌)有限公司 | 一种高效乙胺吡嗪利福异烟片及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02300140A (ja) * | 1989-05-12 | 1990-12-12 | Yamanouchi Pharmaceut Co Ltd | 薬物のシクロデキストリン包接体及びその製造法 |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| CN1029080C (zh) * | 1992-06-26 | 1995-06-28 | 佛冈县新技术研究开发部 | 利福平软膏的配制方法 |
| IT1291362B1 (it) * | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
| DE19911097A1 (de) * | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
| US6500463B1 (en) * | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| US6699505B2 (en) * | 2000-10-17 | 2004-03-02 | Massachusetts Institute Of Technology | Method of increasing the efficacy of antibiotics by compexing with cyclodextrins |
-
2002
- 2002-10-28 US US10/281,533 patent/US7001893B2/en not_active Expired - Fee Related
- 2002-11-06 WO PCT/IB2002/004705 patent/WO2004041284A1/en not_active Ceased
- 2002-11-06 EP EP02783368A patent/EP1581226B1/de not_active Expired - Lifetime
- 2002-11-06 JP JP2004549396A patent/JP2006509742A/ja active Pending
- 2002-11-06 AT AT02783368T patent/ATE386527T1/de not_active IP Right Cessation
- 2002-11-06 CN CNA028300661A patent/CN1713913A/zh active Pending
- 2002-11-06 AU AU2002347434A patent/AU2002347434A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004041284A1 (en) | 2004-05-21 |
| US7001893B2 (en) | 2006-02-21 |
| EP1581226A1 (de) | 2005-10-05 |
| JP2006509742A (ja) | 2006-03-23 |
| AU2002347434A1 (en) | 2004-06-07 |
| CN1713913A (zh) | 2005-12-28 |
| US20040082541A1 (en) | 2004-04-29 |
| EP1581226B1 (de) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE386527T1 (de) | Einschlusskomplex von tuberkulostatischem rifampicin mit beta-cyclodextrin oder 2- hydroxypropyl beta-cyclodextrin und ein prozess zur herstellung desselben | |
| ATE420117T1 (de) | Kovalent an hyaluronsäure oder dessen derivate gebundene taxane | |
| SG130189A1 (en) | Substituted indole-o-glucosides | |
| WO2007095506A8 (en) | Oligosaccharide modification and labeling of proteins | |
| UA86042C2 (en) | Substituted indazole-o-glucosides | |
| WO2004058171A3 (en) | Antibodies against gpr64 and uses thereof | |
| ATE463539T1 (de) | Verbesserter pigmentabstand | |
| NO20072066L (no) | Cyklodekstrininnlemmelseskomplekser og fremgangsmater ved fremstilling derav | |
| MX2007003470A (es) | Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa. | |
| DE502006006107D1 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| Cai et al. | Metal-assisted assembly and stabilization of collagen-like triple helices | |
| DE502006008912D1 (de) | 2,6-naphthylreste enthaltende verbindungen | |
| MX2007002470A (es) | Fenilaminotiazoles sustituidos y su uso. | |
| WO2004099388A3 (en) | Cbl-b polypeptides, complexes and related methods | |
| DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
| TW200500327A (en) | Volatile copper(I) complexes for deposition of copper films by atomic layer deposition | |
| WO2007007982A3 (en) | Glucose uptake modulator and method for treating diabetes or diabetic complications | |
| DE502007002353D1 (de) | Verfahren zur herstellung von cyclischen ketonen | |
| DE602004023475D1 (de) | Verfahren zur herstellung von zinkpulver-agglomeraten und diese enthaltenden artikel | |
| NO20082852L (no) | Faramsoytisk blanding samt bruk av alfa-hydroksy karbonylforbindelser som reduksjonsmidler | |
| WO2005117543A3 (en) | N-sulfonylcarboximidamide apoptosis promoters | |
| WO2007059116A3 (en) | Geldanamycin derivatives and pharmaceutical compositions thereof | |
| WO2004013122A3 (de) | Oktupolare moleküle als organische halbleiter | |
| TW200622024A (en) | Copper(I) complexes for deposition of copper films by atomic layer deposition | |
| DE50110561D1 (de) | Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |